Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Halozyme Therapeutics

- PMLiVE

Deaths cause Amgen to drop stomach cancer drug

Increase in patient mortality in patients taking rilotumumab during trial

UK flag

UK knows ‘almost nothing’ about pancreatic cancer

Celgene-sponsored survey shows 64% of people know little about the disease

- PMLiVE

US judge cuts billions from Takeda/Lilly Actos payment

Court rules that companies must now pay damages of $36.8m rather than $9bn

- PMLiVE

US investigates Novo Nordisk manufacturing issues

Issues subpoena related to insulin plant in Kalundborg, Denmark

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Celgene’s Abraxane authorised by Health Canada

Drug can now be used as first-line treatment for metastatic pancreatic cancer

- PMLiVE

FDA approves pain drug that has reduced risk of abuse

Purdue’s Targiniq ER developed to deter snorting and injection

- PMLiVE

BMJ accuses Boehringer of withholding Pradaxa data

Claims current FDA recommendation for anticoagulant may be flawed

- PMLiVE

Boehringer goes on PR offensive over Pradaxa report

Takes to social media to defend its position on the anticoagulant ahead of tonight's Channel 4 news report

- PMLiVE

FDA adds blood clot warning to testosterone products

Warns of risk of developing deep vein thrombosis and pulmonary embolism

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links